American Company "Schrödinger" Halts Development of Experimental Drug After Two Patient Deaths in Clinical Trial

The American company "Schrödinger" (Schrödinger) announced on Thursday, August 14, the suspension of the development of its experimental drug "S.G.R 2921" after reporting two patient deaths during the early phase of clinical trials.

The drug was being tested on patients suffering from "high-risk myelodysplastic syndromes," which are a group of blood cancers resulting from the bone marrow's failure to produce healthy blood cells in sufficient quantities.

The company explained that preliminary data suggests that the drug may have contributed to the deaths of the two patients with acute myeloid leukemia.

It is noted that the drug showed promising results in preliminary (preclinical) stages in tumor resistance, which led the company to previously indicate the possibility of its future use alongside standard care treatments. However, "Schrödinger" decided to halt development at this time due to these unexpected results.